Semaglutide denied for missing prior authorization by Aetna?

BMI >=30, OR BMI >=27 with comorbidity. 6-month comprehensive weight management program. Continuation requires >=5% weight loss at 3-6 months.

Aetna CPB 0040 explicitly allows continuation if patient achieves >=5% weight loss at 3-6 months — document if applicable. Cosmetic denials: resubmit with ICD-10 E66.01 + comorbidity codes (E11.9, I10, G47.33). Aetna requires physician medical-necessity attestation.

Aetna's prior-auth-required denial on semaglutide signals a procedural gap, not a clinical one. The drug isn't being denied on merit — Aetna's automated review (CVS Caremark) found a missing field on the PA submission and bounced it. Resubmit cleanly and most of these clear without further appeal.

Use Aetna's specific GLP-1 PA form — varies by state and plan; pull from Availity.com or the Aetna provider portal. Required fields with chart documentation:

• BMI in past 12 months with the visit date and the measured (not calculated) BMI from clinical visit.
• Comorbidity ICD-10 codes — never narrative descriptions. Use E66.01 morbid obesity, I10 hypertension, E78.5 dyslipidemia, E11.9 T2DM, G47.33 obstructive sleep apnea, M16 hip osteoarthritis, M17 knee osteoarthritis, K90.81 NAFLD.
• 6-month comprehensive weight management program with frequency (monthly visits with PCP, RD, exercise physiologist, or behavioral health), content (calorie target stated numerically, exercise prescription with type/duration/frequency, behavioral intervention component), and progress (weight at each visit with trajectory).
• Step-therapy documentation for phentermine/topiramate or Contrave (dates, doses, outcomes) OR contraindication with chart citation.
• Continuation criterion if renewal: ≥5% weight loss at 3-6 months with explicit starting and current weight.
• Prescriber attestation that lifestyle modification continues during pharmacotherapy — Aetna requires this as a separate field.

Aetna's automated reviewer applies strict checklist matching. A field with "yes" but no supporting chart documentation gets flagged as incomplete and the auto-denial fires. Always attach the chart documentation that supports each yes — pulled progress notes, RD encounter notes, or a retrospective summary letter from the prescriber stating the patient was enrolled in a comprehensive program with the specific elements.

For renewals, the dispositive criterion is the weight loss percentage at 3-6 months. Aetna treats <5% as treatment failure even if the patient is otherwise tolerating the drug well and showing biomarker improvement. If the response was 4% or borderline, frame as continuing improvement with projected ≥5% by month 6 — cite the specific trajectory and lab improvements (A1c reduction, lipid improvement, BP improvement) as additional medical-necessity arguments.

A common Aetna-specific trap: Aetna's PA form has a field for "prescriber attestation of lifestyle modification continuation." If this checkbox isn't ticked, the auto-denial fires regardless of the other documentation. Always tick it AND attach a brief prescriber letter confirming continuation.

The federal regulatory hook: ERISA §503(g) requires the plan to disclose what documentation was missing when the PA was denied. If Aetna auto-denied without listing the gap, the appeal can compel disclosure under 29 CFR §2560.503-1(g)(1)(iv) and restart the PA clock.

ERISA §503(f)(2)(i) urgent-care expedited appeal applies if the patient is currently on the medication and the PA renewal is delayed. Document the run-out date in the appeal to trigger urgent classification — 72-hour timeline forces fast review.

The Aetna-specific procedural lever: cite the CPB 0040 version date in the appeal. CPB 0040 was last revised in 2024.

Closing tactical tip: submit the PA through the Aetna provider portal directly, not via pharmacy fax — fax submissions are processed slower (5-7 days additional) and have higher denial rates due to OCR errors on chart documentation.